agilon health

Intrinsic pricing power is modest because revenues are capitated and largely defined by CMS funding and negotiated percentage‑of‑premium with payors. 2026 saw constructive rate support and improved percentage‑of‑premium terms, but this is not company‑controlled pricing; leverage sits with payors and policy.

Latent pricing upside exists in better RAF capture and quality bonuses, not list‑price increases. Dependence on external rate notices and contracting cycles makes pricing power structurally limited.